8-K: Barinthus Bio Announces Third Quarter 2024 Results and Clinical Trial Progress

Barinthus Biotherapeutics reported its third quarter 2024 financial results, highlighted by a $15 million revenue boost and progress in its clinical trials for hepatitis B, celiac disease, and prostate cancer.

Summary

• Barinthus Biotherapeutics provided a business update and announced its financial results for the third quarter of 2024.
• The company completed enrollment in the HBV003 trial for VTP-300 in chronic hepatitis B, with 121 participants enrolled.
• The first-in-human Phase 1 trial for VTP-1000 in celiac disease was initiated in September 2024.
• Enrollment was completed in the PCA001 trial for VTP-850 in prostate cancer, with 22 participants enrolled.
• An additional $15 million in revenue was received from Oxford University Innovation due to royalties from prior sales of Vaxzevria by AstraZeneca.
• The company expects this additional cash to fund research and development plans into the second quarter of 2026.
• The company's cash position was $106.1 million as of September 30, 2024, compared to $117.8 million as of June 30, 2024.
• Net cash used in operating activities was $18.2 million in the third quarter of 2024.
• Revenue for the third quarter of 2024 was $15.0 million, compared to nil in the second quarter of 2024.
• Research and development expenses were $11.1 million in the third quarter of 2024, compared to $11.7 million in the second quarter of 2024.
• General and administrative expenses were $13.4 million in the third quarter of 2024, compared to $7.2 million in the second quarter of 2024.
• The net loss attributable to shareholders was $8.1 million, or $(0.21) per share, in the third quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial progress and a significant revenue boost, offset by a net loss and increased administrative expenses. The overall sentiment is positive due to the progress in clinical trials and the extended cash runway.

Positives

• The company completed enrollment in multiple clinical trials, including the HBV003 trial for VTP-300 and the PCA001 trial for VTP-850.
• The initiation of the first-in-human trial for VTP-1000 in celiac disease is a significant milestone.
• The $15 million revenue boost from royalties provides additional funding for research and development.
• The company has sufficient cash to fund operations into the second quarter of 2026.
• The company is presenting updated data from the VTP-300 program at a major liver disease conference.

Negatives

• The company experienced a net loss of $8.1 million in the third quarter of 2024.
• General and administrative expenses increased significantly to $13.4 million due to a $7.7 million loss on foreign exchange.
• The company's cash position decreased from $117.8 million to $106.1 million during the quarter.
• Net cash used in operating activities was $18.2 million in the third quarter of 2024.

Risks

• The company's financial performance is subject to fluctuations in foreign exchange rates.
• The company's research and development activities are subject to the risks of clinical trial delays and failures.
• The company's ability to fund its operations is dependent on its cash position and access to capital.
• The company's future success is dependent on the successful development and commercialization of its product candidates.

Future Outlook

The company expects to announce updated data from the VTP-300 program in the fourth quarter of 2024 and data from the VTP-1000 and VTP-850 trials in the first half of 2025. The company also expects its available resources to fund operating expenses and capital expenditure requirements into the second quarter of 2026.

Management Comments

• Dr. Leon Hooftman, Chief Medical Officer, stated that they continue their strong execution on clinical trials.
• Dr. Leon Hooftman mentioned that they expect a data rich fourth quarter from the VTP-300 chronic hepatitis B program.

Industry Context

This announcement reflects the ongoing efforts in the biopharmaceutical industry to develop novel immunotherapies for chronic infectious diseases and autoimmunity. The company's focus on T-cell guided therapies aligns with current trends in the field.

Comparison to Industry Standards

• The completion of enrollment in multiple clinical trials is a positive sign, as many biotech companies face challenges in patient recruitment.
• The $15 million revenue from royalties is a significant boost, as many clinical-stage companies rely heavily on funding rounds.
• The cash runway into the second quarter of 2026 is relatively strong compared to other companies in the sector, which often have shorter cash runways.
• The net loss of $8.1 million is within the expected range for a clinical-stage biotech company, but the increase in general and administrative expenses is a point of concern.
• The company's focus on hepatitis B, celiac disease, and prostate cancer aligns with areas of high unmet medical need, similar to other companies such as Arbutus Biopharma in HBV and various companies in the oncology space.

Related Party Transactions

• The company received $15 million in license revenue from related parties, specifically from Oxford University Innovation.

Stakeholder Impact

• Shareholders will be encouraged by the clinical trial progress and the additional revenue.
• Employees will benefit from the extended cash runway, providing job security.
• Patients with chronic hepatitis B, celiac disease, and prostate cancer may benefit from the company's product candidates.
• Creditors will be reassured by the company's improved financial position.

Next Steps

• The company will announce updated data from the VTP-300 program at AASLD The Liver Meeting 2024.
• The company will announce data from the single ascending dose part of the Phase 1 AVALON trial of VTP-1000 in the first half of 2025.
• The company will announce results of the Phase 1 PCA001 trial of VTP-850 in the first half of 2025.

Key Dates

Keywords

Barinthus Bio, Biopharmaceutical, Immunotherapy, Clinical Trials, Hepatitis B, Celiac Disease, Prostate Cancer, VTP-300, VTP-1000, VTP-850, Financial Results, Revenue, Research and Development, Cash Position